Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination chemotherapy regimen consisting of three classes of cytotoxic agents frequently used in the treatment of advanced gastrointestinal cancers, particularly metastatic gastric and colorectal cancer. The regimen includes: - A taxane (such as paclitaxel or docetaxel), which stabilizes microtubules and inhibits cell division. - Irinotecan, a topoisomerase I inhibitor that prevents DNA unwinding and replication. - A fluoropyrimidine (such as 5-fluorouracil or capecitabine), which inhibits thymidylate synthase, disrupting DNA synthesis. This combination is typically used in patients who have previously been treated with other regimens containing these agents individually or in different combinations. It is not marketed under a unique brand name but represents a multi-agent protocol tailored for refractory or advanced-stage disease[4][6]. The specific drugs within each class may vary depending on institutional protocols and patient factors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on taxane + irinotecan + fluoropyrimidine.